Pet Stem Cells

Overview

Akira Pet MSCs are allogeneic UCT-WJ-MSCs specially processed for veterinary use. Unlike adipose or bone marrow-derived MSCs (the most common veterinary MSC sources), umbilical cord-derived MSCs are younger, more proliferative, and produce a richer immunomodulatory secretome^{[1] [2]} — providing superior therapeutic outcomes for chronic inflammatory, degenerative, and autoimmune conditions in companion animals.

Related: Stem Cells Overview • Equine/Camelid Stem Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

How Pet MSCs Work

Companion animal osteoarthritis, dysplasia, atopic dermatitis, IBD, chronic organ disease (liver, kidney, cardiac), and post-surgical recovery share the same underlying driver seen across species: chronic low-grade inflammation and progressive fibrosis outpacing the tissue's own regenerative capacity. Autologous adipose- or bone marrow-derived MSCs are already established in veterinary regenerative medicine for several of these indications, but require an invasive harvest procedure from an often already-compromised patient (elderly, arthritic, or systemically ill) and are constrained by that patient's own age-related decline in MSC yield and potency, documented in the human/rabbit MSC-aging literature.^{[3] [4]} Allogeneic UCT-WJ-MSCs are collected non-invasively at birth from banked donor tissue, are younger and more proliferative than adipose/bone marrow sources harvested from an adult patient, and produce a richer immunomodulatory secretome — enabling off-the-shelf treatment at the time of diagnosis without a harvest-and-expansion delay, while retaining the low immunogenicity that allows repeated allogeneic dosing across multiple canine and feline clinical trials without adverse immune reactions.^[5]

Immunomodulation & Anti-Inflammatory Effect: PGE2, IL-10, and TGF-β are well-established core MSC immunomodulatory mediators that suppress macrophage and T-cell-driven inflammation, consistent with the mechanism proposed across canine/feline OA, atopic dermatitis, and IBD studies.

Anti-Fibrotic & Organ-Protective Paracrine Signaling: HGF and anti-fibrotic miRNA cargo (including miR-29^[6]) support hepatocyte and renal tubular cell survival, modulating albumin-induced renal tubular inflammation and fibrosis,^[7] relevant to chronic liver disease, hepatitis, and CKD in aging cats and dogs.

Cartilage & Joint Matrix Support: Intra-articular MSC delivery supports chondrocyte survival and reduces synovial inflammatory cytokine production, improving gait and pain scores in osteoarthritis and dysplasia.

Skin Barrier & Pruritus Reduction: MSC and MSC-derived extracellular vesicle cargo reduce JAK/STAT-driven inflammatory signaling in canine atopic dermatitis, improving skin barrier function and reducing pruritus.^[8]

Cardiac Paracrine Support: VEGF and anti-apoptotic cargo support myocardial tissue in early cardiomyopathy, mirroring paracrine mechanisms studied in human and preclinical MSC cardiac models.

Key Biomarkers & Characterization (MSC)

Potential Applications

• Osteoarthritis & Hip/Elbow Dysplasia — intra-articular MSC injection for joint regeneration
• Atopic Dermatitis & Allergic Skin Conditions — systemic immunomodulation
• Inflammatory Bowel Disease (IBD) — mucosal regeneration, anti-inflammatory
• Chronic Liver Disease & Hepatitis — hepatoprotective paracrine effects
• Kidney Insufficiency / CKD — renoprotective anti-fibrotic effects
• Cardiomyopathy — paracrine cardiac support
• Post-surgical Tissue Regeneration — accelerated healing
• Anti-Aging / General Wellness — vitality, immune optimization, senescent cell reduction

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical Evidence (MSC)

Akira Pet Neural Stem Cells

Canine cognitive dysfunction, degenerative myelopathy, IVDD-associated spinal cord compression, TBI, post-seizure injury, and vestibular/ataxic presentations are neurodegenerative or neurotraumatic conditions with few or no disease-modifying veterinary treatments — management is largely supportive (anti-inflammatories, physical rehabilitation, symptomatic seizure/vestibular control) rather than regenerative. Early proof-of-concept work in companion animals has already shown that direct neural precursor cell delivery can meaningfully reverse cognitive decline (autologous skin-derived neural precursor injection reversing canine dementia-like syndrome in a published veterinary trial,^[10] and a pilot study of stem cell/extracellular vesicle treatment improving cognitive and mobility function in geriatric dogs^[11]), but these approaches rely on autologous harvest or stereotactic neurosurgical delivery that limits practical adoption. UCT-WJ-MSC-derived neural progenitors are intended to supply the same BDNF/GDNF/NGF/NT-3 neurotrophic and remyelinating cargo via a banked, allogeneic, off-the-shelf cell product administered by intrathecal or systemic routes rather than stereotactic brain injection.

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Neurotrophic Support & Neurogenesis: BDNF and NGF cargo activate TrkB/TrkA signaling, supporting hippocampal neuron survival and synaptic maintenance — directly relevant to canine cognitive dysfunction, where restoring aged-brain BDNF expression toward youthful levels has been associated with cognitive improvement in dogs, consistent with the enhanced neurogenic secretome profile of UC-MSC-derived neurospheres.^[12]

Axonal Support & Remyelination: GDNF and NT-3 cargo support motor neuron survival and oligodendrocyte-mediated remyelination, relevant to the upper motor neuron degeneration of degenerative myelopathy and the compressive spinal cord injury of IVDD — an application area where extracellular vesicle-based approaches are an emerging therapeutic strategy^[13] and human umbilical cord MSC transplantation has supported functional recovery after acute traumatic spinal cord injury.^[14]

Neuroinflammation Resolution: miR-146a and miR-21 cargo, part of a broader class of MSC-exosome miRNAs shown to suppress microglial activation and polarize microglia toward an anti-inflammatory phenotype after traumatic brain injury,^{[15] [16]} are proposed to limit secondary injury expansion during the subacute recovery window following TBI, seizure activity, or acute IVDD-associated spinal cord injury — a mechanism consistent with NF-κB/Bcl-2 pathway regulation of apoptosis observed in other neurodegenerative disease models.^[17]

Homing to Injury Sites: neural-lineage progenitors retain chemotactic responsiveness to injury-associated signaling, supporting concentration of neurotrophic cargo at the site of spinal cord compression, brain lesion, or vestibular/cerebellar dysfunction following systemic or intrathecal delivery.

They secrete BDNF, GDNF, and NGF, home to neural injury sites, and provide remyelination support — addressing major unmet needs in veterinary neurology.

Key Biomarkers & Characterization (Neural)

Potential Neurological Applications

• Canine Cognitive Dysfunction (CCD/dog dementia) — neurogenesis, BDNF delivery
• Degenerative Myelopathy — axonal support, neuroinflammation reduction
• Intervertebral Disc Disease (IVDD) — spinal cord regeneration
• Traumatic Brain Injury (TBI) — BBB stabilization, lesion volume reduction
• Post-seizure Brain Damage — neural repair, GABAergic support
• Ataxia, Tremors, Vestibular Disease — motor circuit support

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical Evidence (Neural)

Direct veterinary RCT data is limited; evidence below is drawn from MSC-derived extracellular vesicle spinal cord injury studies and MSC/NSC-exosome studies in human neurodegenerative disease, pending controlled veterinary trials.